The risk of sudden cardiac arrest and ventricular arrhythmia with rosiglitazone versus pioglitazone: real-world evidence on thiazolidinedione safety
Abstract Background The low cost of thiazolidinediones makes them a potentially valuable therapeutic option for the > 300 million economically disadvantaged persons worldwide with type 2 diabetes mellitus. Differential selectivity of thiazolidinediones for peroxisome proliferator-activated recept...
Main Authors: | Charles E. Leonard, Colleen M. Brensinger, Ghadeer K. Dawwas, Rajat Deo, Warren B. Bilker, Samantha E. Soprano, Neil Dhopeshwarkar, James H. Flory, Zachary T. Bloomgarden, Joshua J. Gagne, Christina L. Aquilante, Stephen E. Kimmel, Sean Hennessy |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2020-02-01
|
Series: | Cardiovascular Diabetology |
Subjects: | |
Online Access: | http://link.springer.com/article/10.1186/s12933-020-00999-5 |
Similar Items
-
Premedication with pioglitazone prevents doxorubicin-induced left ventricular dysfunction in mice
by: Takaaki Furihata, et al.
Published: (2021-05-01) -
Antimicrobial screening of new 5-(chromene-3-yl) methylene-2,4-thiazolidinediones
by: Cristina Nastasă, et al.
Published: (2015-08-01) -
A Cost-Effectiveness Analysis Comparing Glargine Versus Rosiglitazone or Pioglitazone for Patients Failing Metformin Plus a Sulfonylurea
by: Spaeth, Brianne, et al.
Published: (2008) -
The effect of metformin and thiazolidinedione use on lung cancer in diabetics
by: Mazzone Peter J, et al.
Published: (2012-09-01) -
Biological potential of thiazolidinedione derivatives of synthetic origin
by: Sucheta, et al.
Published: (2017-12-01)